Profile data is unavailable for this security.
About the company
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.
- Revenue in EUR (TTM)1.16bn
- Net income in EUR167.74m
- Incorporated--
- Employees3.19k
- LocationDiaSorin SpAvia Crescentino sncSALUGGIA 13040ItalyITA
- Phone+39 161487526
- Fax+39 161487670
- Websitehttps://www.diasorin.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitrolife AB | 311.27m | -334.52m | 2.90bn | 1.12k | -- | 2.51 | -- | 9.30 | -28.06 | -28.06 | 26.11 | 96.72 | 0.1836 | 3.65 | 6.16 | 3,276,182.00 | -19.72 | -4.57 | -20.43 | -4.78 | 57.48 | 58.38 | -107.41 | -21.89 | 2.43 | 8.48 | 0.1379 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Gerresheimer AG | 2.00bn | 115.11m | 3.42bn | 11.91k | 29.73 | 2.31 | 11.16 | 1.71 | 3.33 | 3.33 | 57.96 | 42.82 | 0.5838 | 4.00 | 6.68 | 171,666.00 | 3.42 | 3.31 | 4.63 | 4.75 | 29.35 | 29.72 | 5.86 | 5.94 | 0.5053 | 4.59 | 0.4425 | 42.68 | 9.54 | 7.79 | 20.81 | 9.00 | 23.42 | 1.68 |
| Ambu A/S | 705.67m | 60.34m | 4.16bn | 4.82k | 78.10 | 6.12 | 37.62 | 5.90 | 1.69 | 1.69 | 19.80 | 21.60 | 0.7459 | 2.18 | 7.17 | 1,140,165.00 | 6.38 | 3.81 | 7.37 | 4.62 | 58.88 | 59.37 | 8.55 | 5.43 | 1.51 | 74.38 | 0.0961 | 22.89 | 7.45 | 12.88 | 80.65 | -13.00 | 6.67 | -- |
| Sectra AB | 159.39m | 39.38m | 4.27bn | 1.22k | 115.37 | 31.19 | 88.64 | 26.78 | 2.32 | 2.32 | 9.40 | 8.59 | 0.6136 | -- | 3.63 | 1,503,436.00 | 15.16 | 15.75 | 28.08 | 29.52 | 47.01 | 64.95 | 24.71 | 19.59 | -- | -- | 0.027 | 0.00 | 26.84 | 4.06 | 14.25 | 16.58 | 48.37 | -- |
| SCHOTT Pharma AG & Co KgaA | 948.56m | 150.41m | 4.59bn | 4.65k | 30.44 | 5.98 | 21.69 | 4.84 | 1.00 | 1.00 | 6.31 | 5.10 | 0.7434 | 4.34 | 4.07 | 204,166.20 | 11.82 | -- | 16.42 | -- | 34.18 | -- | 15.90 | -- | 1.06 | -- | 0.1086 | -- | 9.43 | -- | 21.11 | -- | -- | -- |
| Getinge AB | 2.93bn | 227.44m | 5.04bn | 11.89k | 23.74 | 1.95 | 12.64 | 1.72 | 9.48 | 9.48 | 122.36 | 115.57 | 0.6168 | 2.48 | 7.04 | 2,839,084.00 | 4.81 | 5.31 | 6.35 | 6.98 | 46.27 | 47.83 | 7.79 | 8.69 | 0.6455 | 13.07 | 0.2136 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| Carl Zeiss Meditec AG | 2.07bn | 203.20m | 5.05bn | 4.95k | 24.78 | -- | -- | 2.44 | 2.28 | 2.28 | 23.14 | -- | -- | -- | -- | 428,397.90 | -- | 9.56 | -- | 11.72 | 55.12 | 57.84 | 9.84 | 13.15 | -- | -- | -- | 34.47 | 9.80 | 10.28 | -1.20 | 18.09 | 26.79 | 14.87 |
| ConvaTec Group PLC | 1.97bn | 137.25m | 5.40bn | 10.13k | 39.43 | 3.64 | 16.21 | 2.74 | 0.056 | 0.056 | 0.8036 | 0.6061 | 0.5965 | 2.47 | 5.89 | 163,070.70 | 4.15 | 2.36 | 4.74 | 2.73 | 55.96 | 55.03 | 6.96 | 4.34 | 1.27 | 2.96 | 0.4604 | 127.29 | 3.37 | 3.18 | 107.15 | -6.93 | 12.37 | 31.41 |
| DiaSorin SpA | 1.16bn | 167.74m | 5.76bn | 3.19k | 34.17 | 3.40 | 18.97 | 4.96 | 3.01 | 3.01 | 21.78 | 30.31 | 0.3668 | 1.26 | 6.09 | 359,117.20 | 5.28 | 10.30 | 5.78 | 11.50 | 64.81 | 66.70 | 14.40 | 21.25 | 1.89 | 12.28 | 0.3892 | 24.71 | -15.64 | 11.40 | -33.65 | 0.2167 | 16.49 | -- |
| Amplifon SpA | 2.32bn | 161.58m | 5.88bn | 14.38k | 36.33 | 5.16 | 13.25 | 2.53 | 0.7153 | 0.7153 | 10.27 | 5.03 | 0.6229 | 21.46 | 10.96 | 161,594.30 | 4.33 | 4.31 | 6.53 | 5.81 | 24.56 | 59.01 | 6.95 | 7.28 | 0.3992 | 6.12 | 0.5921 | 34.26 | 6.65 | 10.66 | -12.21 | 9.08 | 12.68 | 15.68 |
| Ypsomed Holding AG | 577.95m | 82.58m | 6.06bn | 2.30k | 73.41 | 9.31 | 37.53 | 10.49 | 5.74 | 5.74 | 40.18 | 45.26 | 0.5587 | 5.40 | 4.96 | 238,875.00 | 7.98 | 4.41 | 12.40 | 6.81 | 34.47 | 27.26 | 14.29 | 7.38 | 0.5967 | 20.89 | 0.293 | 20.50 | 10.25 | 3.86 | 52.83 | 5.44 | 8.64 | 29.46 |
| Demant A/S | 3.00bn | 355.05m | 7.94bn | 21.50k | 22.36 | 6.18 | -- | 2.65 | 11.98 | 10.92 | 101.23 | 43.36 | 0.7192 | 2.03 | 5.68 | 1,034,778.00 | 8.52 | 8.27 | 11.68 | 13.23 | 75.45 | 74.14 | 11.85 | 11.34 | 1.06 | 5.58 | 0.6244 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
Data as of Sep 23 2024. Currency figures normalised to DiaSorin SpA's reporting currency: Euro EUR
12.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 1.05m | 1.88% |
| T. Rowe Price International Ltd.as of 30 Jun 2024 | 957.68k | 1.71% |
| Wellington Management Co. LLPas of 19 Sep 2024 | 861.67k | 1.54% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 838.98k | 1.50% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 793.23k | 1.42% |
| Invesco Advisers, Inc.as of 05 Sep 2024 | 713.16k | 1.28% |
| Shareholder Value Management AGas of 29 Feb 2024 | 499.10k | 0.89% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 448.92k | 0.80% |
| Financi�re de l'�chiquier SAas of 31 Mar 2024 | 422.15k | 0.76% |
| Mediolanum Gestione Fondi SGRpAas of 28 Mar 2024 | 373.83k | 0.67% |
More ▼
Data from 28 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
